Foundayo™ and palpitations

Heart rate in the Foundayo™ documents

Foundayo™ is a once-daily orforglipron tablet, which the ACHIEVE-3 publication describes as a non-peptide GLP-1 receptor agonist ^[8]. The label’s other adverse reactions include a short tachycardia paragraph built from three terms: tachycardia, heart rate increased and sinus tachycardia ^[1]. It also reports that, in a dedicated study at 1.4 times the peak levels of the top dose, orforglipron did not cause clinically significant QTc prolongation, a measure of the heart’s electrical recovery ^[1].

What other studies add

ACHIEVE-3 compared orforglipron 12 and 36 mg with oral semaglutide 7 and 14 mg for 52 weeks in people with type 2 diabetes on metformin. The authors reported a greater rise in pulse with orforglipron, and noted it alongside more stomach side effects and more stopping for adverse events ^[8]. The trial was open label.

A 2026 network meta-analysis of GLP-1 medicines in people without diabetes found that all of them raised heart rate on average, and estimated the largest rise for orforglipron, about 7 beats per minute against placebo ^[9]. Its orforglipron estimate rested on a single phase 2 trial, so it is less certain than the label’s figures from two large trials.

Making sense of the heart-rate findings

• An average rise of 4 to 5 beats per minute is small, and many people will not feel it. Palpitations are a sensation, so measured pulse and what you notice do not always match.
• Tachycardia in the label pool was three times as common on Foundayo™ as on placebo, but still uncommon at 3% ^[1].
• Palpitations in the registries were scattered: more on orforglipron than dapagliflozin in ACHIEVE-2, and equal to placebo in ACHIEVE-5 ^[6][7].
• The label gives no timing for the heart-rate rise, does not say whether it eases, and does not explain it.
• Heart disease was uncommon in the label’s trials; 3% had coronary artery disease ^[1]. Data in people with significant heart disease are limited, so a cardiologist’s view matters if that applies to you.

Other label effects that can make your heart race

Low blood sugar: Foundayo™ can cause it, more so with insulin or a sulfonylurea ^[1]. The Medication Guide lists a fast heartbeat, sweating, shakiness and feeling jittery among its signs ^[2].

Fluid loss and low blood pressure: nausea, vomiting and diarrhoea can lead to dehydration, which MedlinePlus says can cause a rapid heartbeat ^[1][13]. Low blood pressure was reported in 2% on Foundayo™ against 0.5% on placebo ^[1].

Serious allergy: a very rapid heartbeat appears among the Medication Guide’s signs of a serious allergic reaction, together with swelling and trouble breathing ^[2].

How orforglipron raises heart rate is not explained in the label. It is reported across the GLP-1 class ^[9], but the mechanism behind the larger rise seen with orforglipron has not been established.

Common causes unrelated to the tablet

MedlinePlus lists frequent triggers of palpitations ^[10]:

• Anxiety, stress, panic and fear.
• Caffeine, nicotine and excessive alcohol.
• Decongestants such as pseudoephedrine or phenylephrine, diet pills and stimulant drugs.
• Exercise and fever.
• Less often, heart disease, a valve problem, abnormal potassium, an overactive thyroid or some asthma, blood pressure and heart medicines.

What general sources suggest

MedlinePlus suggests cutting down on caffeine, nicotine and other stimulants, learning ways to manage stress and anxiety, trying relaxation or breathing exercises, staying active and not smoking ^[10]. Once a provider has checked for a serious cause, it advises not watching your heartbeat too closely, but contacting your provider if the palpitations suddenly increase or change ^[10].

Cleveland Clinic says occasional palpitations without other symptoms are worth mentioning to your provider, and that palpitations that get worse or happen more often warrant a call ^[11]. If you have diabetes, checking your blood sugar during an episode helps tell a low from other causes ^[12].

Points specific to Foundayo™

If you measure your pulse at home, doing it at rest and at similar times of day makes small changes easier to judge against the label’s average rise of a few beats per minute ^[1]. Bring the readings, not just the impression, to your appointment.

Foundayo™ is raised no sooner than every 30 days, up to a maximum of 17.2 mg ^[1]. Table 7 shows a slightly larger pulse rise on 17.2 mg than on 5.5 mg in Trial 1 ^[1], so noting palpitations against your dose steps is useful context for your prescriber.

Foundayo™ is a trademark of Eli Lilly and Company. PepLabo is not affiliated with or endorsed by Eli Lilly and Company.